STC2: A Novel and Regulable Protector of Vascular Smooth Muscle Cells

Ai-hua Zhang,Fen-fen Liu,Hong-dong Huang,Xu Liu,Zong-li Diao,Dai Deng,Wen-hu Liu
DOI: https://doi.org/10.2139/ssrn.4010831
2022-01-01
SSRN Electronic Journal
Abstract:Background: Apoptosis of vascular smooth muscle cells induced by high phosphate is a critical mechanism of chronic kidney disease-related vascular disorders. Clinically available intervention is limited. This study was designed to investigate the expression of sanniocalcin 2 (STC2) in human aortic smooth muscle cells (HAoSMCs), and whether it can be regulated by calcium-sensing receptor (CaSR) to antagonize high phosphate-induced apoptosis.Results: HAoSMCs were cultured in vitro. Some levels of STC2 gene transcription were detected in HAoSMCs with common culture medium by qPCR, suggesting its background expression. CaSR agonist resulted in significant increase of STC2 mRNA and protein levels with or without high phosphorate. Confocal microscope revealed that STC2 induced by CaSR agonist co-located with plasma membrane and endoplasmic reticulum, but not with mitochondria. STC2 overexpressing almost abolished high phosphate-induced HAoSMCs apoptosis by caspase-3 and TUNEL positive cells analysis, whereas STC2 silencing caused worsened apoptosis. CaSR agonist treatment significantly reduced caspase-3 levels and TUNEL positive cells induced by high phosphate. In STC2 silencing cells, the protective effect of CaSR agonist disappeared.Conclusion: The present study demonstrates for the first time in vitro that HAoSMCs can express STC2, which can be positively regulated by CaSR. Up-regulation of STC2 can antagonize high phosphate-induced apoptosis in HAoSMCs.
What problem does this paper attempt to address?